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Abstract
Background: Former studies already revealed the anti-neoplastic properties of the anti-infective agent Taurolidine
(TRD) against many tumor species in vitro and in vivo. Its anti-proliferative and cell death inducing capacity is largely
due to its main derivative Taurultam (TRLT). In this study it could be demonstrated, that substance 2250 - a newly
defined innovative structural analogue of TRLT - exhibits an anti-neoplastic effect on malignant pancreatic carcinoma in
vitro and in vivo.
Methods: The anti-neoplastic potential of substance 2250 as well as its mode of action was demonstrated in extensive
in vitro analysis, followed by successful and effective in vivo testings, using xenograft models derived from established
pancreatic cancer cell lines as well as patient derived tissue.
Results: Our functional analysis regarding the role of oxidative stress (ROS) and caspase activated apoptosis showed,
that ROS driven programmed cell death (PCD) is the major mechanisms induced by substance 2250 in pancreatic
carcinoma. What is strongly relevant towards clinical practice is especially the observed inhibition of patient derived
pancreatic cancer tumor growth in mice treated with this new substance in combination with its sharply higher
metabolic stability.
Conclusion: These encouraging results provide new therapeutical opportunities in pancreatic cancer treatment
and build the basis for further functional analysis as well as first clinical studies for this promising agent.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is the most le-
thal common cancer, usually diagnosed at an advanced
stage when curative therapy is almost impossible [1]. It is
the fourth most common cause of cancer-related death in
Europe [2] and in the US [3]. The pancreatic adenocarcin-
oma typically has a poor prognosis with a five year relative
survival rate of 4–5% [4]. In fact, incidence and mortality
of PDAC are almost equal. Surgical resection is the only
potentially curative therapy for pancreatic cancer.
Because of the poor outcome associated with surgery
only, the role of adjuvant therapies has been extensively
evaluated. A series of studies revealed, that chemother-
apy with gemcitabine or fluorouracil improves the over-
all survival of patients with pancreatic adenocarcinoma
[5–8]. In the majority of cases a complete resection of
the tumor is impossible. Therefore a palliative chemother-
apy may be conducted to prolong survival and improve
the quality of life. In these cases new combination therap-
ies like FOLFIRINOX are investigated in clinical trials or
are in use [7, 8] However, current chemotherapeutic
agents are still disappointing due to their poor response
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and high toxicity. New and innovative agents have to be
found to expand the therapeutic opportunities.
Taurolidine (TRD) is a substance derived from the
aminosulfonacid taurine. Owing to its anti-inflammatory
and its anti-microbial qualities, it has been clinically
used primarily in peritonitis and catheter related blood
stream infections [9]. 1997 Jacobi et al. could show for
the first time, that TRD also applied an anti-proliferative
and anti-neoplastic activity in vitro and in vivo [10]. This
anti-neoplastic and apoptosis inducing effect could also
be verified by other research groups [11] in a variety of
cell lines derived from malignant tumors e.g. glioblast-
oma [12], melanoma [13], mesothelioma [14] and colon
carcinoma [15]. Furthermore, latest reports about the
systemic application of TRD in patients with gastric car-
cinoma and glioblastoma revealed promising results with
almost absence of toxicity [16, 17].
The favorable safety profile of TRD renders this com-
pound to a promising novel agent for the oncological
care. However, the metabolic stability of TRD is limited
due to its short half-life [18].
This study was designed to analyze a novel compound
related to Taurultam (TRLT), the main derivative of TRD.
Substance 2250 is a structural analogue of TRLT and is an
oxathiazine derivative (Fig. 1). The respective Sulfon-
amides are promising substances due to their antibacterial
and anti-neoplastic activity. The 1.4.5-Oxathiazin deriva-
tives, like the new substance 2250, are almost unexplored
whereas 1.2.3-Oxathiazin derivatives are already identified,
mainly as artificial sweeteners [19]. However, no represen-
tative studies are published analyzing the anti-neoplastic
effects of the substance 2250 so far. The aim of this study
was to investigate the anti-neoplastic activity on malignant
pancreatic cancer in vitro and in vivo.
Methods
Cell lines and culture conditions
Six different human pancreatic cancer cell lines were used
for our experiments: AsPC-1 (CLS Cell Lines Service,
Eppenheim, Germany), BxPC-3 (ATCC – LGC Standards
GmbH, Wesel, Germany), MiaPaca-2 (ATCC – LGC
Standards GmbH, Wesel, Germany), Panc-1 (CLS Cell
Lines Service, Eppenheim, Germany) and Panc-TuI
(ATCC – LGC Standards GmbH, Wesel, Germany). Cells
were passaged fewer than 6 months after receiving from
the mentioned cell banks. Authentication was analyzed by
STR analysis. MiaPaca-2, Panc-1 and Panc-TuI cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM).
The remaining cell lines (AsPC-1, BxPC-3) were main-
tained in RPMI 1640. All cultures were supplemented
with the antibiotics penicillin (100 U/ml), streptomycin
(100 U/ml) and 2 mM L-Glutamine. AsPC-1 cells were
further supplemented with 1 mM Sodium Pyruvate. Cells
were grown as monolayer and cultured in 25cm2 flasks at
37 °C and 5% CO2 in humidified atmosphere.
Tissue
Different human pancreatic cancer tissues were used for
the in vivo experiments:
Bo70, adenocarcinoma, UICC IIb.
Bo 80, adenocarcinoma, UICC IIb.
Reagents
The 2250 and TRLT ultrapure powder (kindly provided
by Geistlich Pharma AG, Wohlhusen, Switzerland) was
dissolved in double distilled Water (ddH2O), sterile
filtered, set to a physiological pH and freshly prepared
once per week.
MTT cytotoxicity assay
Cells were seeded to a density of 3.5 × 104 cells/well in
96-well plates and incubated for 24 h to obtain a sub con-
fluent monolayer. To examine the dose-response of 2250
and TRLT regarding its anti-neoplastic activity, cells were
incubated with increasing concentrations (100, 200, 500,
1000, 1500, 2000 μmol/l) and ddH2O as control for 6, 12,
24 and 48 h. 4 h before the measurement 10 μl yellow
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
liumbromid) reagent (5 mg/ml) was added to the test
media. Yellow MTT is converted by viable cells into violet
Formazan crystals. The test media was discarded and
50 μl DMSO (Dimethylsulfoxide) was applied. After an
incubation time of 5–10 min the viability of cells could be
analyzed by using a microplate absorbance reader by
measuring the OD (optical density) (Tecan trading AG,
Switzerland). The amount of violet Formazan is directly
proportional to the amount of viable cells. The assay was
performed in 4–6 independent experiments with consecu-
tive passages.
BrdU proliferation assay
Cells were seeded to a density of 4 × 104 cells/well in
96-well plates and incubated for 24 h to obtain a sub
Taurultam Substance 2250
Fig. 1 Molecular structure of substances TRLT and 2250. Substance
2250, 1.4.5-oxathiazan-dioxid-4.4, is an oxathiazine derivative like
TRLT with a moleculare weight of 137.15 g/mol
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confluent monolayer. To examine the dose-response of
2250 and TRLT regarding its anti-proliferative activity,
cells were incubated with increasing concentrations of
2250 (100, 200, 500, 1000, 1500, 2000 μmol/l) and
ddH2O as control for 6 h and submitted to BrdU prolif-
eration assay (5-bromo-2-deoxyuridine)-ELISA (Roche
Applied Science, Mannheim, Germany) according to the
manufacturer’s instructions. Based on the incorporation
of the thymidine analogue BrdU during DNA synthesis,
the amount of synthesized DNA is detected using a
microplate absorbance reader (Tecan trading AG,
Switzerland). BrdU assays were performed with 8 rep-
licates of three independent experiments with con-
secutive passages. The incubation time of 6 h has been
shown to be appropriate for the BrdU proliferation
assay in previous experiments.
Flow Cytometry analysis
Cells were seeded to a density of 2 × 105 cells/well in 6-
well plates and incubated for 24 h to obtain a subcon-
fluent monolayer. Different concentrations of 2250
(200, 500, 1000, 1500, 2000 μmol/l) and ddH2O as con-
trol were used for 24 h and 48 h before analyzed by
FACS analysis. FACS analysis was performed in 4–6 in-
dependent experiments with 2–4 consecutive passages.
Cells were fixed in 200 μl binding buffer (Bender Med-
Systems, Vienna, Austria). Subsequently, 5–10 μl Annexin
V-FITC (BD Biosciences, Heidelberg, Germany) was
added to the cell suspension and incubated for 15 min at
room temperature in the dark. Thereafter, 10 μl Propidiu-
miodide (PI) (Bender MedSystems, Vienna, Austria) was
added. Cells were analyzed immediately using a flow
cytometer (FACS Calibur BD Biosciences, Heidelberg,
Germany) for Annexin V-FITC (apoptotic) and PI
(necrotic) binding. Dot plots and histograms were an-
alyzed by CellQuest Pro software (BD Biosciences,
Heidelberg, Germany).
Functional mechanisms
To get insights into functional mechanisms of drug
effects cells were additionally treated with the radical scav-
enger N-acetylcysteine NAC (5 mmol/l) (Sigma Aldrich,
Munich, Germany) or the pan caspase inhibitor-zVad
(2 μmol/l) (Enzo Life Sciences, Lörrach, Germany) be-
fore analysis by FACS or MTT standard procedure as
already described. Concentrations of 500 and 1000 μmol/l
2250 with an incubation time of 24 h were used for co-in-
cubation assays in all cell lines.
The direct impact of 2250 on the cellular level of reactive
oxygen species (ROS) was analyzed using the Cellular ROS/
Superoxide Detection Assay KIT (Abcam, Cambridge, UK)
following the manufactures instructions.
Analysis of the maximal tolerable dose
Acute toxicity
For determining the acute toxicity of substance 2250 in
nude mice, mice (each group n = 8–10) were treated
intraperitoneal (ip) with different concentrations (500,
1000, 1500, 2000 mg/kg*BW) once, followed by control
of body weight and general vital function. A loss of 20%
of body weight over 48 h was classified as toxic.
Chronic toxicity
To assess the chronic toxicity mice were treated with
different concentrations of substance 2250 (500, 1000,
1500 mg/kg*BW) on alternating days for 3 weeks. Control
of body weight and general vital function were measured
as well. A loss of 20% of body weight over 48 h was classi-
fied as toxic.
Analysis of metabolic half-life in blood
For determining the metabolic half-life of the new sub-
stance 2250 in the blood of nude mice, a colorimetric
assay using NASH-Reagent and protein free serum was
used. The serum level was analyzed 1 h and 25 h after
treatment with the substance 2250 (500 mg/kg*BW).
Animal studies
Five-week-old female NMRI Foxn1nu/Foxn1nu mice
(Janvier, France) were acclimated into a 12-h light
cycle-controlled environment 1 week before initiation
of the study. The animals were allowed standard labora-
tory food and water ad libitum. Mice were anesthetized
by inhalation of Isofluran. 5 × 106 cells of different pancre-
atic adenocarcinoma cell lines (MiaPaca-2 and PancTU-I)
or tumor tissue fragments were administered subcutane-
ously in the flank region. After implantation, the recipient
mice were monitored for general health status and the
presence of subcutaneous tumors. Tumor volume was
determined by measuring tumor diameters (measurement







(a = larger axe, b = smaller axe).
Following randomization (two groups, n = 10) the sys-
temic influence of 2250 on tumor growth after intraperito-
neal (ip) application were investigated. As the metabolic
half-life of 2250 in nude mice was found to be 13.8 h, a
dosing schedule of every second day was chosen for the in
vivo experiments. Group1: substance 2250 500 mg/kg*BW
on alternating days, group 2: control group Ringer’s
solution 300 μl was applied ip on alternating days. The
treatment was initiated when the tumor volume reached
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200 mm3 and the tumor volume was measured every sec-
ond day for 2–3 weeks. The experiment was terminated ei-
ther after an application period of 3 weeks or when the
tumor reached a volume of 1000 mm3.
Statistics and calculations
Results of FACS-analysis (percentage of viable, apoptotic
and necrotic cells) as well as results of MTT and BrdU
assay (percentage of living/proliferating cells) are expressed
as means ± SEM. Comparison between experimental
groups with normal distribution was performed using
one-way ANOVA followed by Tukey’s post-hoc test.
For categorical data Fisher’s exact test used if appropriate.
P-values ≤0.05 were considered as statistically significant
and indicated in the figures as follows: *** p ≤ 0.001, **
p ≤ 0.01, * p ≤ 0.05.
For the calculation of metabolic half-life the following
formula was used: G xð Þ ¼ Go 12
 x
t:
(G(x) = serum concentration (24 h), G0 = serum con-
centration (0 h), x = 24 h, t = metabolic half-time)
Results
2250 has a cytotoxic effect on all cell lines in a dose
dependent manner
To determine the effect of substance 2250 on the cell via-
bility the OD (optical density), MTT tests were conducted.
As indicated in Fig. 2, incubation with 2250 in increasing
concentrations (100, 200, 500, 1000, 1500, 2000 μmol/l)
Fig. 2 Effects of 2250 in different malignant cell lines measured by MTT-assay. AsPC-1 (a), BxPC-3 (b), MiaPaca-2 (c), Panc-1 (d) and Panc TuI cells
(e) were incubated with 2250 (100, 200, 500, 1000, 1500, 2000 μmol/l) and ddH2O (control) for 24 h and submitted to a MTT-assay. Values are
means ± SEM of 6 replicates of three independent experiments with consecutive passages. Asterisk symbols indicate differences between control,
which was adjusted to 100% and 2250 treatment. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, n.s. p > 0.05 (one-way ANOVA followed by Tukey’s
post-hoc test)
Buchholz et al. BMC Cancer  (2017) 17:216 Page 4 of 13
for 24 h resulted in a dose dependent reduction of living
cells - as measured by MTT assay. The substance 2250 in
the cell line Panc-TuI was only analyzed up to a concen-
tration of 1000 μmol/l, because this cell line was used add-
itionally for in vivo treatment. The concentrations used in
vitro were the important ones for in vivo treatment.
In all cell lines, even the lowest concentration of
500 μmol/l led to a significant reduction of cell viabil-
ity ranging between 39.4% (± 3.8%) (BxPC-3) and
73.8% (± 3.3%) (Panc-1) which was significantly lower
compared to untreated controls (100%) with ddH2O
(Fig. 2). However, at the following concentration of
1000 μmol/l 2250, the monitored reduction of cell viability
was more than 50% in four out of five cell lines. This pro-
nounced reduction, mediated by 2250 in a concentration
of 1000 μmol/l resulted in values of living cells between
33.3% (± 1.2%) for BxPC-3 and 59.1% (± 2.6%) for PancTuI
(Fig. 2b, e). The maximum dose of 2000 μmol/l led to an
intense cytotoxic effect in all cell lines. As a result, in three
cell lines a proportional doses-effect curve and in BxPC-3
as well as in MiaPaca2 a sigmoid character was observed
(Fig. 2). The effective doses (ED) 50 were varying between
the different cell lines from 221 μmol/l (BxPC-3) to
1100 μmol/l (Panc-1) within an incubation time of 24 h.
2250 inhibits proliferation of all cell lines in a dose
dependent manner
To examine the effect of substance 2250 on cell prolifer-
ation in a culture model, BrdU assays were conducted.
As indicated in Fig. 3, incubation with substance 2250 in
Fig. 3 Effects of Taurolidine (TRD) on cell proliferation in different malignant cell lines measured by BrdU-assay. AsPC-1 (a), BxPC-3 (b), MiaPaca-2
(c), Panc-1 (d) and Panc TuI cells (e) were incubated with 2250 (100, 200, 500, 1000, 1500, 2000 μmol/l) and ddH2O (control) for 6 h and submitted
to a BrdU-assay. Values are means ± SEM of 8 replicates of three independent experiments with consecutive passages. Asterisk symbols on
columns indicate differences between control, which was adjusted to 100% and 2250 treatment. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, n.s.
p > 0.05 (one-way ANOVA followed by Tukey’s post-hoc test)
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increasing concentrations (100, 200, 500, 1000, 1500,
2000 μmol/l) for 6 h resulted in a dose dependent reduc-
tion of proliferating cells. In three cell lines, even a
concentration of 200 μmol/l 2250 was capable of inhibit-
ing proliferation leading to values of proliferating cells
ranging between 12.7% (± 1.3%) (Panc-TuI) and 77.2%
(± 1.6%) (AsPC-1) which was significantly lower com-
pared to untreated controls (100%) with ddH2O (Fig. 3).
The concentration of 500 μmol/l 2250 significantly
inhibited proliferation in all analyzed cell lines. This
inhibition resulted in amounts of proliferating cells be-
tween 4.3% (± 0.6%) for Panc-TuI and 54.3% (± 1.2) for
Panc-1 (Fig. 3 d, e). The maximum dose of 2000 μmol/l
implicated an extended inhibition of proliferation in all
cell lines, so the dose response for cell proliferation
could be characterized as proportional in all five pancre-
atic cancer cell lines (Fig. 3).
Table 1 shows the relative amounts of cell viability and
cell proliferation of three different cell lines upon treat-
ment with substances TRLT and 2250 (2000 μmol/l
each). In all analyzed cell lines substance 2250 shows a
substantial higher impact on cell viability as well as on
cell proliferation. In AsPC-1 and Panc-1 substance 2250
is even twice as effective as TRLT.
2250 induces apoptotic cell death in all cell lines
Additional FACS analysis revealed the impact of sub-
stance 2250 on apoptotic-, as well as on necrotic cell
death. As summarized in Fig. 4, incubation of three cell
lines for 24 h with substance 2250 with a concentration
of 1000 μmol/l and 1500 μmol/l resulted in a significant
reduction of viable cells compared to control treatment
with ddH2O as evaluated by FACS analysis with
Annexin V-FITC and PI. The significant reduction of
cell viability by 1000 μmol/l 2250 was paralleled by a sig-
nificant increase of apoptotic cells in all cell lines (Fig. 4).
Cell viability following incubation with 1000 μmol/l was
varying between 41.1% (±0.7%) for BxPC-3 and 59.0%
(±1.9%) for AsPC-1 cells. The strong impact on cell viabil-
ity was paralleled by a significant apoptotic effect in all cell
lines ranging between 14.2% (± 1.5%) apoptotic cells for
AsPC-1 and 35.0% (± 2.01%) for Panc-TuI. The contribu-
tion of necrosis to the loss of cell viability was smaller.
However, a significant increase in necrotic cells between
16.4% (± 2.5%) for Panc-TuI and 28.9% (± 1.0%) for
BxPC-3 was observed (Fig. 4).
The following incubation with 1500 μmol/l of 2250
showed a pronounced and significant reduction in cell
viability between 28.5% (± 1.5%) for Panc-TuI and 7.6%
(± 0.8%) for BxPC-3 cells. This reduction in cell viability
was also paralleled by a significant increase of apoptotic
cells – but only in two of three cell lines (AsPc-1, Panc-
TuI). In BxPc-3 no significant apoptotic alteration was
detected. However, BxPc-3 cells responded towards
1500 μmol/l with a strong necrotic effect 80.6% (± 1.1%)
which was highest observed among all cell lines and
concentrations (Fig. 4).
The radical scavenger N-acetylcysteine (NAC) and
pancaspase inhibitor z-VAD show divergent effects on
2250 induced cell death
To evaluate the contribution of Caspase or reactive oxy-
gen species mediated cell death to the observed effects
of substance 2250 co-incubation experiments with sub-
stance 2250 and NAC or z-VAD were performed.
In AsPc-1 and Panc-1 cells, co-incubation of 2250
with NAC for 24 h led to a complete protection to-
wards 2250 induced cell death. NAC entirely abrogated
the 2250 induced reduction of viable cells leading to
cell viability, equal to untreated controls (Fig. 5a, d). In
BxPC-3, MiaPaca-2 and Panc-TuI, the co-incubation of
2250 with NAC was characterized by a strong protection
of cell viability. However, there was no complete protec-
tion in the amount of viable cells compared to untreated
controls. The effect could only be characterized as a par-
tial protection (Fig. 5b, c, e).
Further data of FACS analysis of AsPC-1 co-incubated
with 2250 and NAC for 24 h shown in Fig. 5 confirmed
previous results. In contrast to the MTT assay, the FACS
analysis shows this effect on the different cell populations
more in detail. The co-incubation was characterized by a
completely protection against the 2250 induced reduction
of viable cells leading to a significant increase of viable
cells (Fig. 6a). No differences from untreated controls were
detected. Together with a small but significant reduction
of apoptotic cells under treatment with a concentration of
500 μmol/l 2250, a complete reduction of necrotic cells
could be achieved under treatment with 1000 μmol/l 2250
(Fig. 6b, c). Furthermore the cellular level of ROS is sig-
nificantly increased in cells treated with substance 2250.
Fig. 5f provides an exemplary presentation of tested cell
lines. This effect can be reversed by additional treatment
with NAC.
Table 1 Results of MTT and BrdU assay of substance 2250 compared with TRLT in three different cell lines
AsPC-1 BxPC-3 Panc-1
TRLT 2250 TRLT 2250 TRLT 2250
MTT assay cell viability (%) 48.78 ± 2.8 21.00 ± 3.8 36.01 ± 7.3 26.24 ± 0.3 65.24 ± 1.5 24.4 ± 4.6
BrdU Assay cell proliferation (%) 8.5 ± 0.9 3.34 ± 0.2 6.66 ± 0.7 1.0 ± 0.2 16.32 ± 1.2 9.14 ± 0.3
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All pancreatic cancer cell lines which were analyzed
did not show any detectable effect on cell viability after
z-VAD co-incubation (data not shown).
Detection of the maximal tolerable dose of substance 2250
By analyzing the acute toxicity, the highest concentration of
2000 mg/kg*BW was toxic in nude mice. The body weight
was reduced about 1 g in 48 h and the mouse died 5 days
after treatment. For the other concentrations no changes in
body weight and vital function could be observed.
Determining the chronic toxicity it could be observed
that concentrations higher than 1000 mg/kg*BW are
toxic in nude mice. While treatment with 500 mg/
kg*BW no changes in body weight and vital function
could be monitored.
Analysis of metabolic half-life in blood
For determining the metabolic half-life of the new sub-
stance 2250 in blood of nude mice a colorimetric assay
using NASH reagent was used. The alignment of the mea-
sured values of substance 2250 in mice serum after 1 h
and 25 h with the calibration curve yielded a metabolic
half-life of 13.8 h (Fig. 7, Table 2).
2250 induces reduction of subcutaneous tumor growth in
vivo
Finally, to elucidate the effect of substance 2250 in vivo,
we tested the impact of the treatment of xenografts
derived from cancer cell lines and patient tissue in
different tumor mouse models.
As indicated in Fig. 8, the intraperitoneal (ip) applica-
tion of 2250 (500 mg/kg*BW) reduced the subcutane-
ous tumor growth in vivo in tumors induced by
established pancreatic cancer cell lines (MiaPaca-2,
Panc-TuI) as well as in xenograft models from patient
tissue. The ip application of 2250 led to a significant re-
duction of 57% of relative tumor volume in comparison
to the control group after an application period of
3 weeks in tumors caused by the established cell line
MiaPaca-2 (Fig. 8a). In a second tumor model evoked
by the established cell line Panc-TuI (Fig. 8b) almost
the same inhibition of tumor growth was observed by
ip application of 2250 (500 mg/kg*BW). A significant
reduction of 49.7% of relative tumor growth was de-
tected after an application period of 2 weeks. The
tumor volume endpoint of 1000 mm3 was reached after
this treatment period and the experiment was termi-
nated. The subcutaneous tumor, derived from patient
tissue (Bo 70) was analyzed in a separate tumor model
in which a significant reduction of tumor growth of
36.8% under the treatment with substance 2250 could
be observed (Fig. 8c). In a second patient derived xeno-
graft (Bo 80) almost the same inhibition of approxi-
mately 30% could be detected (Fig. 8d).
Discussion
The anti-neoplastic effects of the recently developed,
novel substance 2250 have not been published yet. During
development of the compound, a cytotoxicity test was
performed in the glioma cell line LN 229 which indi-
cated a promising anti-neoplastic capacity of the sub-
stance 2250 (EC 50 = 55 μg/ml after 24 h)
[unpublished data], similar in potency to TRD. The
anti-neoplastic activity of the parent compound TRD
Fig. 4 Effects of 1000 μmol/l and 1500 μmol/l 2250 on viability,
apoptosis and necrosis in different malignant pancreatic cell lines
measured by FACS analysis. AsPC-1 (a), BxPC-3 (b) and Panc-TuI (c)
cells were incubated with 2250 (1000 and 1500 μmol/l) and ddH2O
(control) for 24 h. The percentages of viable, apoptotic and necrotic
cells were determined by FACS-analysis with Annexin V-FITC and
Propidiumiodide. Values are means ± SEM of 4–6 independent
experiments with three consecutive passages. Asterisk symbols on
columns indicate differences between control and 2250 treatment.
*** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, n.s. p > 0.05 (one-way ANOVA
followed by Tukey’s post-hoc test)
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Fig. 5 Effects of NAC on 2250 induced cell death in different malignant cell lines measured by MTT (a-e); impact of 2250 on the cellular level of
ROS (f). AsPC-1 (a), BxPC-3 (b), MiaPaca-2 (c), Panc-1 (d) and Panc TuI (e) cells were incubated with either 2250 (500, 1000 μmol/l), NAC (5 mmol/l)
or the combination of both agents (2250 500, 1000 μmol/l + NAC 5 mmol/l) and ddH2O as control for 24 h and submitted to a MTT-assay. The level of
ROS was analyzed in untreated compared to 2250 treated cells, additional NAC treatment served as a neg. Control (f). Values are means ± SEM of 6
replicates of three independent experiments with consecutive passages. Asterisk symbols indicate differences between control, which was adjusted to
100% and 2250 treatment. *** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, (one-way ANOVA followed by Tukey’s post-hoc test)
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has been demonstrated in many studies on different
cancer entities in vitro as well as in vivo [18, 20, 21]
. Even pilot clinical studies confirmed previous results
[16, 18, 22]. Therefore, the aim of this study was to
analyze anti-neoplastic effects of substance 2250 in
comparison to its structural analogue TRLT, the main
derivative of its effective parent compound TRD.
In the first part of this study we determined dose-
response characteristics and analyzed the relative con-
tribution of apoptosis and necrosis during substance
2250 induced cell death. In all five different malignant
pancreatic cancer cell lines the dose response effects
of substance 2250 were nearly homogenous. We found
a pattern which is characterized by a proportional or
sigmoidal dose effect where increasing concentrations
of substance 2250 led to an increase of cell death after
24 and 48 h. This pattern could be observed for the
cytotoxicity of the substance via MTT assay, as well as
for the anti-proliferative effect by BrdU analysis. This
proportional dose effect pattern, observed during this
study, is analog to those described in several previous
studies for the treatment with TRD [23–26].
Three pancreatic cancer cell lines (AsPC-1, BxPC-3
and PancTuI) also displayed a dose-response relation-
ship concerning the relative distribution of viable,
apoptotic and necrotic cells determined by FACS ana-
lysis, where the amount of viable cells decreased with
increasing concentration of substance 2250. The incu-
bation with 1000 μmol/l of substance 2250 was charac-
terized by apoptotic as well as necrotic cell death
whereby the apoptotic effect was the predominant char-
acteristic. In contrast, the incubation with 1500 μmol/l
of substance 2250 was characterized by a pronounced
necrotic effect in BxPC-3. This effect became more ob-
vious in AsPC-1. Opposite to this, in PancTuI cells
treated with 1500 μmol/l the amount of apoptotic cells
prevailed. This dose depending ratio of viable, apop-
totic and necrotic cells is according to previous studies
with TRD in our group [15] and by others [13, 26].
Regarding the pronounced necrotic effect of rising
concentrations of substance 2250, only speculations are
possible. Whereby, cell culture models could reveal a
potential explanation. Generally, apoptosis is due to
caspase-dependent or independent cell destruction and
to phagocytosis of the apoptotic cells. In a cell culture
setting, which lacks phagocytosis a secondary necrosis
follows, which is characterized by the same appearance
of primary necrosis [27].
In our in vitro studies there is no possibility of phagocyt-
osis by inflammatory cells, because they are not present in
our cell culture model. The marker, used for necrosis (PI)
could ultimately not differentiate between a substance-
induced primary necrosis and a secondary necrosis - due
to the lack of phagocytosis. Another possible explanation
Fig. 6 Effects of NAC on 2250 induced cell death in cell line AsPC-
1 measured by FACS analysis. AsPC-1 cells were incubated with
either 2250 (500, 1000 μmol/l), NAC (5 mmol/l) or the combination
of both agents (2250 500, 1000 μmol/l + NAC 5 mmol/l) and ddH2O
as control for 24 h. The percentage of viable (a), apoptotic (b) and
necrotic (c) cells were determined by FACS analysis. Values are
means ± SEM of 4–6 replicates of three independent experiments
with consecutive passages. Asterisk symbols indicate differences
between control, which was adjusted to 100% and 2250 treatment.
*** p ≤ 0.001, ** p ≤ 0.01, * p ≤ 0.05, n.s. p > 0.05 (one-way ANOVA
followed by Tukey’s post-hoc test)
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might be the induction of a programmed necrosis by sub-
stance 2250 itself, as shown previously for Taurolidine
[26]. Programmed necrosis is, besides apoptosis and au-
tophagy, the third type of programmed cell death, which
involves cell swelling, organelle dysfunction and cell lysis.
Programmed necrosis can be induced by different signal-
ing pathways a. o. via activation of death receptors or cell
stress can induce activation of receptor- interacting-protein
kinases RIP1 and RIP3, which influence mitochondria to
induce ROS increase [27, 28]. Further work is required to
clarify whether substance 2250 lead to the induction of pro-
grammed necrosis on such a high level, at least in BxPC-3
and AsPC-1 at high concentrations.
The second part of this study deals with the contribu-
tion of reactive oxygen species (ROS) to substance 2250
induced cell death and the analysis of another major
cell death associated pathway, the caspase pathway.
Previous studies with TRD revealed an involvement of
ROS 12, 40 [29], triggering apoptosis via caspase-
independent pathways [12, 20], caspase-dependent
pathways 40 [15, 20, 25] as well as necroptosis and au-
tophagy [26]. Furthermore, cell death, induced by ROS,
has been shown to be prevented by applying the radical
scavenger N-acetycysteine (NAC) [12, 25, 29]. Hence,
in this study both the cellular ROS induction upon
treatment and co-incubation experiments with either the
radical scavenger NAC for inhibition of oxidative stress or
the pan caspase inhibitor z-VAD for involvement of the
caspase pathway were performed. Substance 2250 clearly
induced ROS production in all tested cell lines. This effect
could be completely canceled by the radical scavenger
NAC. In line with this result, all analyzed pancreatic
cancer cell lines responded to NAC co-incubation with an
attenuated cell death, induced by substance 2250. Never-
theless, the extent of protection from cell death was diver-
gent between the analyzed cell lines, ranging from partial
protection (BxPC-3, MiaPaca-2, PancTuI) to complete
protection (AsPC-1, Panc-1). In general, ROS is regarded
as being an ambiguous compound in terms of anti-
neoplastic activity [30]. On the one hand, it is able to sup-
port tumor cell proliferation and survival [14, 30]. On the
other hand, excessive ROS generation in tumor cells can
induce cell death. This therapeutic effect is used by many
chemotherapeutics as platinum, arsenic, ascorbate or
piperlongumine [13, 30–32]. In conclusion, the generation
of ROS and the consequent activation of following path-
ways is an obvious explanation of the induction of cell
death by substance 2250 in pancreatic cancer cell lines.
Thus, ROS induced cell death may not be the universal
mechanism of substance 2250, but our experiments high-
light its central role in programmed cell death (PCD).
We also analyzed another major cell death associated
pathway mentioned in the literature referring TRD
induced cell death - the caspase pathway [20, 25, 33].
Among the literature, the activation of the caspase
Fig. 7 calibration curve of metabolic half-life measurement. The calibration curve consisting of five different concentrations of substance 2250
served as a standard for the calculation of the metabolic half-life of substance 2250 in nude mice, which resulted in a value of 13.8 h. The
according measured parameters are shown in Table 2
Table 2 Measured parameters of metabolic half-life calculation
Time of blood
sampling
Relative extinction Concentration in
serum [μg/ml]
1 h 0.475 29.044
25 h 0.128 8.954
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pathway by TRD has been mentioned for several cell
lines, but the findings were divergent between different
tumor entities. Furthermore, caspase independent PCD
induced by TRD was reported in the literature as well
[12, 20]. The analyzed pancreatic cancer cell lines
(AsPC-1, BxPC-3) were not protected via inhibition of
pan-caspases from PCD induced by substance 2250 in our
experiments. Previous studies of our group determined
that pancreatic cancer cell lines were not protected from
PCD caused by TRD, via inhibition of pan caspases, either
[15]. The response observed in pancreatic cancer cell lines
regarding the inhibition of 2250 induced cell death, via the
pan-caspase inhibitor zVAD, leads to the assumption, that
especially for pancreatic cancer cell lines the caspase
dependent PCD plays only a minor role. Therefore, other
pathways like necroptosis or caspase independent pro-
grammed cell death may play a more considerable role.
These pathways are well discussed in the latest literature
related to cancer therapies [34–37]. Further studies in this
field are necessary to clarify the involvement of caspase
independent types of programmed cell death following the
treatment with the substance 2250.
On the basis of this foregone promising in vitro re-
sults, we analyzed the anti-neoplastic effects of sub-
stance 2250 in vivo. Prior to the in vivo studies the
metabolic half-life of the new substance 2250 was deter-
mined, due to the fact that Taurolidine shows a very
short metabolic half-life of only 1–2 h in healthy human
volunteers [22]. Our analysis yielded a metabolic half-life
of substance 2250 of 13.8 h in nude mice, displaying a
much higher metabolic stability compared to TRD. Based
on the fact that mice have a higher metabolism than
humans, it can be assumed, that the metabolic half-life of
substance 2250 in humans is even higher. TRD was previ-
ously found to suppress tumor growth of different tumor
entities in rodents [10, 11, 20, 21, 38–45]. The ip applica-
tion of TRD inhibits the ip tumor growth of colonic carcin-
oma [42], mesothelioma [31], malignant melanoma [13, 45]
and pancreatic carcinoma [43, 44]. It could also be shown
that the intravenous (iv) application of TRD decreases the
ip tumor growth as well [38, 40, 41, 46]. Existing studies
also have experiences with the effect of TRD application
on subcutaneous tumor growth. In colon carcinoma the
subcutaneous tumor growth was not influenced by TRD
application [38, 40], whereas the subcutaneous tumor
growth in malignant melanoma [13, 47] and prostate car-
cinoma [48] was inhibited by TRD instillation ip and iv.
Therefore our experimental in vivo study was based
on the hypothesis that substance 2250 could also in-
hibit the growth of pancreatic cancer after ip adminis-
tration in an established cell line model and a xenograft
model with patient tissue in nude mice. We observed a
significant reduction of subcutaneous tumor growth in
tumors induced by established pancreatic cancer cell
lines (MiaPaca 2, PancTuI) as well as in xenograft
models from patient tissue (Bo70, Bo80). In tumors
caused by established pancreatic cell lines, the ip appli-
cation led to a significant reduction by approximately
50% of relative tumor volume in comparison to the
controls. These results were confirmed by the xenograft
MiaPaca 2 (in vivo)
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Fig. 8 Effects of 500 mg/kg*BW 2250 on the subcutaneous tumor growth in nude mice in vivo. Nude mice with tumors of MiaPaca-2 (a), Panc-
TuI (c) or patient tissue (b, d) were incubated with 2250 (500 mg/kg*BW) and ddH2O (control) for up to 3 weeks. The tumor volume was
measured on alternating days for up to 3 weeks. Asterisk symbols indicate differences between control and 2250 treatment. *** p ≤ 0.001, ** p ≤ 0.01,
* p ≤ 0.05, n.s. p >0.05 (one-way ANOVA followed by Tukey’s post-hoc test)
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models derived from patient tissue, where a reduction
of relative subcutaneous tumor volume by 30–40% was
observed after treatment with substance 2250.
Conclusion
In conclusion, this is the first study providing an evalu-
ation of substance 2250 induced cell death among several
pancreatic cancer cell lines in vitro and inhibition of pan-
creatic tumor growth in vivo. Substance 2250 is character-
ized by a clear dose response relationship due to the fact
that all analyzed cells lines were susceptible to substance
2250 induced cell death. Functional analysis of the in-
volvement of ROS driven and caspase activated PCD
showed, that ROS plays a fundamental role inducing cell
death in pancreatic carcinoma. In contrast, PCD by cas-
pase activation was less important. Furthermore substance
2250 seems to effectively inhibit pancreatic cancer tumor
growth in mice, simultaneously displaying a higher meta-
bolic stability, which will be a strong benefit towards
clinical practice. These encouraging results are the basis
for further functional analysis and initial clinical studies
for this promising agent. It remains to be seen whether
2250, in analogy to TRD, also exerts anti-inflammatory
activity by reducing pro-inflammatory cytokines.
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